Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad5F35-LMP1/LMP2 DC Vaccine + Celecoxib in Metastatic NPC
NCT00589186Phase 2Unknown
- Sponsor
- National Cancer Centre Singapore
- Start
- Nov 2007
- Primary completion
- Dec 2009
- Modality
- Gene Editing, Whole Cell Cancer Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Ad5F35-LMP1/LMP2-transduced autologous dendritic cells in nasopharyngeal carcinoma (NPC), sponsored by National Cancer Centre Singapore. Primary endpoint: Clinical Benefit Rate at 14 weeks. Status: unknown.
02
Drugs
Ad5F35-LMP1/LMP2-transduced autologous dendritic cells
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT00589186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00589186.